- 2-23-2024 LSUHS Secures New Patents
- 2-15-2024 LSUHS Holds 6th Annual Research Celebration
- 2-6-2024 LSUHS and Volunteers of America North Louisiana Launch New Mental Health Program: EpiCenter
Shreveport, La. – Five new patents have been awarded to current or retired LSU Health Shreveport faculty members in fiscal year 2024 (July 2023-June 2024). These patents not only protect the intellectual property of the inventors but offer new processes or treatment methods options that significantly advance science and medical care.
The achievement of being issued a patent is a testament to each inventor and their team’s expertise, creativity, and passion for scientific advancement in their respective fields, and the institution's mission to support innovation and discovery. It is also a testament to their dedication and diligence as the process of filing and being awarded a patent can be one that is complex and lengthy. These recently issued patents were filed in 2017, 2020, and 2021, respectively. The types of patents awarded are defined as utility or divisional patents. The United States Patent and Trademark Office (USPTO) may grant a utility patent to anyone who invents or discovers a new and useful process, machine, article of manufacture, or composition of matter, or any new and useful improvements of these. A divisional patent is filed after the initial parent application and has been divided out of this earlier patent to get more protection for multiple inventions.
Details of the five patents issued are below. For more information on any of these patents and to explore collaborative opportunities with LSU Health Shreveport, contact the Office for Technology Transfer at firstname.lastname@example.org.
Patent Title: Methods of treating neurodegenerative disorders
Inventors: Yuping Wang, MD, PhD and Xiao-Hong Lu, PhD
Patent Number: US-11707491 (Utility Patent)
Overview: This method of therapy introduces a novel approach to treating neurodegenerative disorders and brain injuries. Utilizing neural progenitor cells derived from the mammalian placenta, this method offers hope for millions affected by conditions such as cerebral palsy, Alzheimer's disease, and Parkinson's disease. This innovative treatment is designed to offer a targeted therapy to repair and regenerate damaged neural tissue, providing a new pathway to recovery and health improvement compared to current treatment options.
Patent Title: Targeting the TLK1/NEK1 axis in prostate cancer
Inventors: Arrigo De Benedetti, PhD; et.al.
Patent Number: US-11826369 (Utility Patent)
Overview: Prostate cancer remains a leading cause of cancer-related morbidity and mortality among men worldwide. Despite advancements in treatment, the progression to castrate-resistant prostate cancer (CRPC) represents a significant challenge, often leading to fatal outcomes. This novel therapeutic approach introduces a combination therapy designed to significantly improve the benefits of androgen deprivation therapy (ADT) and delay the progression to CRPC.
Patent Title: Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
Inventors: James A. Cardelli, PhD, et.al.
Patent Number: US-11744827 (Divisional)
Overview: Metastatic cancer remains the leading cause of cancer-related deaths worldwide, with tumor invasion being a critical step in the progression to metastatic disease. This innovative therapeutic strategy focuses on inhibiting lysosome trafficking within tumor cells, a novel target that has shown promise in slowing tumor invasion and the formation of metastatic lesions, particularly in brain cancer where tumor invasion is a predominant cause of mortality.
Patent Title: Method, device, and system for bone fixation
Inventors: Giovanni F. Solitro, PhD; R. Shane Barton, MD, MPH, FAAOS, FAOA; and J. Steven Alexander, PhD
Patent Number: US-11806025 (Utility Patent)
Overview: This surgery tool is designed to revolutionize the way bone surgeries are conducted on animals, particularly in mouse models. This innovative device simplifies the complex and technically challenging process of bone fixation, offering a seamless, efficient, and more reproducible method for researchers and surgeons alike.
Patent Title: Treatment for methamphetamine cardiovascular disease
Inventors: Chris G. Kevil, PhD and Gopi Kolluru, PhD
Patent Number: US-11883426 (Utility Patent)
Overview: In the face of the growing epidemic of methamphetamine abuse and its severe cardiovascular repercussions, this novel therapeutic approach emerges as a beacon of hope. Leveraging the potent effects of hydrogen sulfide (H2S) donors, this treatment is designed to counteract the endothelial dysfunction caused by methamphetamine use, offering a promising solution to in caring for patients with methamphetamine-related cardiovascular dysfunction.
On Thursday, February 15, LSU Health Shreveport (LSUHS) held their 6th Annual Research Celebration, where members of the community and LSUHS employees and students were invited to hear about the past year's accomplishments of the LSUHS Office for Research.
Some highlights shared include:
- More than $23 million in extramural grant funding awarded to LSU Health Shreveport in fiscal year 2023, and more than $20 million awarded in fiscal year 2024 to date.
- More than 100 clinical trials with a high rate of diversity in participants, and LSUHS being the No. 1 site for participant enrollment in 2023 for two national studies: the Surgical Timing and Rehabilitation) Trial for Multiple Ligament Knee Injuries (STaR) and the Black and African American Connections to Parkinson’s Disease (BLAAC-PD) study.
- New grants and collaborations that have been awarded and will begin in 2024.
- A tour of the Center of Excellence for Emerging Viral Threats BSL-2, BSL-3 and training laboratories in the new Center for Medical Education.
LSU Health Shreveport and the Office for Research also celebrated the 2024 Research Excellence Award Winners which are listed below.
- Excellence in Extramural Funding – Quanguang Zhang, PhD
- Excellence in Translational Research – Elizabeth Disbrow, PhD
- Excellence in Innovation – Arrigo De Benedetti, PhD
- Research Rising Star – Krista Rodgers, PhD
- Community Champion – Mr. W. Clinton “Bubba” Rasberry, Jr.
- Dr. Sushil Jain was recognized with a Career Service Awards for his 42+ years of service to the institution and contributions to science
Shreveport, La. – LSU Health Shreveport (LSUHS) and Volunteers of America North Louisiana (VOANLA) have partnered together to create a mental health program, EpiCenter. EpiCenter provides assessment and treatment for youth and adults who have recently begun experiencing psychosis. The new program is operated by VOANLA’s behavioral health division and supported by LSU Health Shreveport’s Psychiatry and Behavioral Medicine Department.
Psychosis is a condition that affects the mind and causes a loss of contact with reality. Individuals experiencing psychosis may have trouble understanding what is real or not real. According to the National Institutes of Health, studies estimate that between 15 and 100 people out of 100,000 develop psychosis each year, and psychosis primarily begins in early adulthood, although the condition can have an earlier onset for some individuals.
EpiCenter’s treatment team consists of LSUHS psychiatry and behavioral medicine physicians and VOANLA behavioral health clinicians and counselors. The team utilizes evidence-based models for early intervention and first-episode psychosis treatment, including services such as psychotherapy, psychiatric medication management/primary care, individual, group and family education, case management, and supported employment and education. The EpiCenter also aims to address the unique needs and individual preferences of each client to enhance the outcome of treatment, providing services in the community and home. The multi-disciplinary team works with patients and their families to determine goals and navigate the path towards long lasting recovery and wellness.
”EpiCenter is the first and only center in northwest Louisiana that aims to bring awareness and care to individuals experiencing their first psychotic episode,” said Carolyn Hammond, president and CEO, VOANLA. “This partnership, along with our existing behavioral health programs, allows us to provide a full continuum of services to those in need.”
VOANLA behavioral health clinicians, counselors and other staff oversee patient case management, therapy and other support services while LSUHS physicians provide medication management and other clinical psychiatric care.
“Providing treatment at the first sign of psychosis allows patients to achieve the best outcome. I am so grateful to LSU Health Shreveport, VOANLA and the Louisiana Department of Health Office of Behavioral Health for creating this opportunity for us to serve patients in north Louisiana” shared Dr. Pamela McPherson, Vice Chair Department of Psychiatry and Behavioral Health, LSU Health Shreveport.
Patients may be eligible to participate in the EpiCenter program if they have been experiencing psychosis for less than 3 years, have received a diagnosis of schizophrenia or other psychotic disorder and are willing to be evaluated and treated by healthcare professionals.
VOANLA invites the community to a free, one-hour tour of the EpiCenter on Wednesday, February 7 from 11 a.m. to noon. For more information or to RSVP for the tour, visit https://voanorthla.org/get-connected/#hope-begins-here-monthly-tours.
Public Relations Coordinator
Office: (318) 675-8789
Cell: (318) 787-8321
Research Communications Coordinator
Office: (318) 675-4166